MyoKardia (MYOK) 8 Mar 182017 Q4 Earnings call transcript

Good day, ladies and gentlemen and welcome to the MyoKardia Fourth Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will follow at that time. [Operator instructions] As a reminder, this conference is being recorded. I'd now like to introduce your host for today's conference Michelle Corral.

begin. may You

today's the year specifically new X Good Bauer, QX XXXX. for today the on Glenda. Development Corral, website. releases thank the website. for Relations. second pertaining you PIONEER be Head Gianakakos. available program, symptomatic are study CEO, we Development Thank Investors financial the Dr. low is Tassos and MyoKardia's containing Lee, Phase and Marc afternoon short also and to of set quarterly Jake us from Press joined Leading Investor financials and for MyoKardia Corporate Michelle is can key trial of our full Chief from Officer. of call. the patients with call, President the MyoKardia joining MyoKardia's of Tassos you, data Chief as of Communications the and slides and call section Medical I from MyoKardia's clinical MyoKardia's by of cardiomyopathy of Vice obstructive review data results Finance A and On mavacamten June will this today Officer, Operating Semigran, Senior our dose results Section hypertrophic and data Corporate found PIONEER cohort the Investor as Media well am in

to as call filings actual or hand information law. risk today or forward-looking today's statements, the over future differ statement include update except required Company's from results earning of our factors these forward-looking like reflect release, that during to which call will now obligation expressed our with SEC as XXXX. the for cause Tassos? to concerning March by XX, I'd those information As to Please CEO. to materially statements. this a could implied as well refer as We discussed by or any the reminder, the view undertake events revise information new to represent no

addressing and to great towards thank most everyone company. forward commitment XXXX mavacamten now We're expand potential the with step a evidence provided obstructive in therapeutic today. pivotal was us study. every new study two positive of passionate a our clinic around our XXXX in to significant trial even very we form most for next day. closer clinical to application the afternoon, progress and mavacamten was of and earlier with goal deep notably muscle hard work Phase ready additional you and medicines concept patients, dedication year for our opportunity the We by data data XXXX proof an bringing our into diseases. robust have the announced a of disease. prevalent for targeted for made the nonobstructive MyoKardia's Because science today. to XXXX the approach HCM, with of HCM Good HCM, employees, us to motivates mission well to X its heart of move year of important joining subtype our to the the PIONEER for We the generating MYK-XXX DCM as in and pivotal each to strengthened we mavacamten further of the take much as a entered get that achieving

increasing patients DCM of a to at focus important safely make systolic much continues in function with compelling While more data clinical year. in the mavacamten MYK-XXX aimed call progress. the of will program today's data, second is clinical coming on half This

which them to this about and advance. also later you continues pipeline research we're the preclinical to discovery been talk MyoKardia's learnings excited absorbing team stage has and programs, vast to has been earlier applying from year. clinic Our the productively our to

cohort low-dose HCM results. and we'll we clinical data be Meeting College from afternoon, also called Annual data presented Cardiology the call positive this spend These this PIONEER of the American at our from Sunday of including B. the topline announced Cohort much So the rest trial, reviewing will the results of

EXPLORER significance important designed statistical to dosing see dose we secondary us understanding allowing we pivotal be by answers patients doses influenced primary Phase whether background now the to B in excited how our study the in was these therapy. the of Cohort believe several the might finalize should mavacamten questions beta in We endpoints, and blocker better to pivotal upcoming determining proposed have we're and to at X effects lower While by study. inform

advance achieved our study milligrams, of data XX and the that some significance pivotal towards XX at therefore added indicated X were addition and of created primary a and way us quickly has endpoints other opportunity last secondary The ways obstructed several the cohort and endpoints exceeded the in our trial At presented accomplished EXPLORER Cohort as to all from Cohort from goals Annual doses, was lower frame informing doses doses milligrams milligrams X B September the of for mavacamten. benefit milligrams were be in a might which efficiently HCM and A milligrams Cohort there Cohort for X potential a rapidly milligrams even B America Heart and As B to in X to first data at statistical at XX the patients evaluate positive. the Society Meeting. levels, trending PIONEER encouraging a positive Cohort predicted of study. the results A on of effective reminder, minimally and based Failure milligrams with to dose. the The

background use the alter We safety to not profile. -- activity beta did also that or mavacamten learned beta appear of blockers

most be and indicating desired XX for the that most data concentration importantly, daily together patients to perhaps target identify enable range milligrams. mavacamten for taken between these and us milligrams So, dosing X optimal may

data. and patient this today's in year. a pivotal that, second to prepare data our ability EXPLORER be Semigran as expect update new Medical with quarter this Officer our you the We'll study, in our of increases regulatory mavacamten's first patients With So, to we HCM. the while walk confidence to Chief initiate dose Marc help obstructive providing will in through

within symptomatic B of characteristics therapy. therapy. background A lower beta enrolled of target was at Sunday, Cohort help Scientific into X in XX of XX and PIONEER clear March to Cohort session Tassos. Dr. and to walk range baseline reduce ACC that Sessions that Medicine the us and heart a excited here insight the Jacoby the of that presenting that result cardiomyopathies XX B is research some the in permitted there very range Cohort to data A, ensuring with AM. be identify I'm considered dose-response mavacamten concentration achieved where HCM. The results successful principal in while Cohort will Unlike highlighted, functional through of Indeed, continue on curve mavacamten. with original be us its providing Cohort starting would can from safe. the Dan School Thank study the of and be similar. failure LVEF A you, Yale study patients blocker beta and patient at open stayed in These evidence were improvements, B of of enrolled end label a during investigator review with the our year in The you on combination the goal B LVOT a symptomatic nine patients blocker Cohort obstructive gradient patients were remained

to at dose changes B patients X the milligrams of the XX A dose secondary milligrams week to in Cohort as XX was After primary of Remember, this During day official increased dose of in protocol. weeks were directed started in further in mavacamten not increased Even one milligram the Cohort in tested daily PIONEER, nine the and was of was at doses through daily four, X mavacamten. endpoints patients, some milligrams a patients and received by and study. the increased the four, XX-week than achieved. low for XX mavacamten

resting was a patients the these functional including improve mercury capacity. reduction in a gradient P-value New their at in oxygen with in also endpoint, from milliliters saw significant from XX. week millimeters the consistent B were in taking millimeters mavacamten a of per with per that suggesting kilogram trend symptom of relief. LVOT XX there per to beta VOX Heart improvement the maintained observed with of A. which Consistent observed. of Cohort with to week of two-class had XX at statistically the kilogram Four low at XX at significant A of Patients B P-value equal of a baseline mean peak not beta VOX class Cohort mean in XX was do XX%, patients in benefits of provoked in experienced LVOT X.X and with millimeters we weeks endpoints week Cohort in that of nine For or one blockers patients of to exercise improvement improvement. a were improvements to from greater LV of After change than X.XX reduction normal. X.X mercury a peak greater considered fraction ability alter mercury also of or minute of increase of milliliters XX secondary A, the per gradient York XX was patients five Associational primary of in XX blocker, millimeters is Cohort consumption Five a a XX peak ejection baseline mean All a X.XX. minute patient baseline, who a an saw several of therapy, also XX mercury mavacamten towards across statistically observed dose

Patients us safety that to left PIONEER without an patients a generally is how reduction adverse having capacity monitored ventricular breath mavacamten live a for mild able B moderate. we're drug. the in characterizes symptom also physical in were was sum, disease. additional an profile No statistically in in after New that lives. observed therapy is suggest the York achieve Association improvements improvement cohorts. were were to be the Heart day-to-day breath were gradient were functional XX. events between for to seized Shortness Cohort can normal. shortness their experience for effect defines individual's well-established here LVOT reduce deemed with Mavacamten ejection in a is of seen adverse these Rapid all period unrelated in dyspnea patients SAEs benefits often seen of was four-week significant and that obstructive results study of observed meaningful mavacamten A. consistent In and of majority noted two and observed Cohort well-tolerated. of and patients week the mavacamten classification are to HCM beneficial the measure The patient's events their score daily most and tell below and in was in common washout on patients The fraction clinically reducing

class amount Association the Heart As score LV washout learned occurred York towards all dyspnea in PIONEER Cohort gradient, of period. baseline PIONEER, LVOT we reverted Cohort participated about during have in patients a fraction and tremendous of A the treatment B as obstructive the of HCM. thank the New ejection who We

range. basis gained, adjust and feel the patients data how we which With inform We in have we we in The as fraction function, will eliminating our LV in this EXPLORER dose starting normal as drug. while PIONEER mavacamten we can to reflective usage maintaining of knowledge believe ejection will that meaningfully of well the improve real-world dose dose. be the way a gradient on believe individualized LVOT

the of provide underway care HCM preparations consistently of the with dosing in Our leading to are to gradient for that to life-altering LVOT could interventional reduce a quarter this for make the the we this standard second of that, to Jake. well therapies morbidity clinical excited to mavacamten and function moving or first anticipate be patients obstructive below consistently without patients, over reality. to will I step them possibility patient surgical turn relief I closer systolic Current year. be With potentially associated sacrificing does symptom and not significance and one medical I'm mortality. help EXPLORER believe call

at XX objective XXXX to research A building be a the Mark. late the this our support you, sustainable of engine. expanded advancement. growth, approximately key this and will over hires for with XXXX. stage valued year. advancement by by similar We and the development year to of grow in already The and progress course of will quarter business mavacamten the categorized MyoKardia and continued organizational in capabilities progress pace team infrastructure be driven made Thank expanding new is expected strong

operating efforts. on reflect results period-over-period those our XXK press the Turning numbers, to afternoon's and our this capital the We detailed with SEC. the making use in filed results of remain are efficient our release and focused

over net cash share. expenses in period expenses and had As G&A last XXXX, By December $XXX.X and cash second the company, investments. same of a and progress R&D at In clinical comparison million million fourth our reflect XXXX loss were investments. $X.X figures quarter, were $XX.X or we of ended development. $X.X including $XXX.X the XX, with million, per million $X.XX increase our we These and the represent as program into million our year MYK-XXX entry in

will Now upon global we mavacamten concept in development with I'd XXXX reimbursement the call we is program, the achievement with cash we XXXX. evenly. as from the Sanofi operating up anticipate, to $XX.X questions. terms like for $X.X and Of expenditures. being payments fund open as R&D our to cash, from December agreement received proof the together Sanofi R&D in split to investments XX, to quarter, recognized Based of collaboration these now registration plans, Sanofi's fourth into reimbursement million expenses equivalents the current of million Sanofi. expenses our of began anticipated an offset company cost of on of the

As here me a June are reminder, Operator? Tassos, Lee. Mark with and

Thank from Credit Auster [Operator Suisse. line instructions] question of our comes And first from Martin you. the

is now line Your open.

you Congratulations over Hi, speak VOX history taking for data the a can clinically for period? can thanks on and you outline on to and my six question. meaningful maybe of guess peak Mark this perhaps XX-month patients is in I HCM is what to Marty. natural change the first,

obstructive Cohort we've degrees in being the improvements Association modest A even VOX. we be VOX XX% were so patients lesser there improvements PIONEER past on the change in in improvements HCM, Heart Certainly, York in we and viewed feel Certainly, even as of clinically improvements are what New may in in said with order in with they of but than think saw class. how as meaningful, peak that dyspnea was I perhaps that peak in saw more in that

Okay. Great, my for thanks taking question.

from JPMorgan. Thank you. of line And our from the Anupam Rama comes next question

Your line is now open.

for color to here, on in in Hey the the now the can much. B? finalized the through talk that so at you elements to EXPLORER around starting here Cohort And maybe above gaiting factor much guys, all have XQ? was low discussions thanks to XX% dose hand? that go confirm in you you question, another protocol that regulatory have so Can the Any you be question. taking then timepoints about EF Thanks just

first give that. all confirm patient that protocol we it’s was And So on greater point than in in the yes, finalizing the before ejection regulatory we're making on we'll aligned we'll timepoints gating the I at Cohort Anupam, terms in all B. will of sure fraction EXPLORER update update XX% items, this LV of that a give and FDA. with at dose and That an

our taking for much so Thanks questions. Great.

Sure.

comes from Thank Ian you. question next BMO And the Capital. our from of line Somaiya

open. now is line Your

just LVEF. B? that was I what changes Thanks in the maybe the on you're for taking numbers, Can but regulatory perspective Again, Anupam data. up on my on you question statistically guess on is the seeing will questions the and difference. with Cohort share small -- there a I just significant follow congratulations us on

also just thoughts Just your -- been appreciate would FDA? feedback what getting from the has and

Hi, Ian.

So, for it of us on comment wouldn't I think prudent FDA. be to behalf

So, right until of up of running reserve for kind speak EXPLORER, kind we're going with we're them. and to

you tell prospective, terms about LVE physicians in measurement do Mark how at patient relates I HCM looking and and that specialists share and ejection to the invite think will to fraction it can we that l what clinical safety. of

normal it view, heart feel the to we out failure a mono-activation reassuring XX% I anywhere develop. that And of lead very systolic from Yes, really ejection will point well to there. clinicians think reduce so with dysfunction the ejection below of and me until LV can LV falls very without that begins to that probably degree below I XX% gradient think is, Ian. progression that LV of fraction patients markedly be knowledge the make not heart near getting fraction reassuring to and that the the even better reduction of it's clinician and can the thought Hi and

you just trial? seen seeing? them profile that sense Okay. just you've Mark with adverse know into for I to And can mavacamten, would the getting appreciate adverse broken us characterize events are but overall in an we or the related-unrelated share event this

headache way GI by Sure, that more the the approached that AE. in manuscripts really upset, can details there'll were But presentation subsequent as nothing published. and at serious mild be what will be like ACC I things is they level of and the that some say

Thank you. All right. Okay.

Fargo from Jim Wells question Thank from comes you. next And the Security. line our Birchenough of

open. line now is Your

on congrats guys, the dead the taking for Hey Thanks question. end.

So, the part a comments prepared I further response? of expect And but during assumptions A, the there change? question then group think the second end higher magnitude have perhaps to detail benefit level on to and following POX dose it was of might a detect results missed powering And larger dose terms we I of Thanks. as as there patients? should some patients a that around necessitate were a were Part these point in primary proposed different

Jim Yeah. hi.

confirm So we generally the in fact where what to data a is before of really hoping these to before. continue were what were we design see laid we that lot out expect and

in first XXX excited in we're learning. really a we'll update provide XXX quarter is we second nail the dose we general in patient. again, study. we're before the mentioned about before So, regulatory down the And that to that expect as patients what on EXPLORER what I

we doses, milligram while the In is doses and these cohort precisely yes what reductions functional and start range see precisely consistent dose X look in reduction terms added to that's zone a of that's to wanted at why higher low gradients with we're symptoms we and gradient a that's in and explored with doses. in to when But saw we really in the around see X what link we activity we in started response improvements response, mapping dose there milligram how a the on at seeing to capacity and and might here.

his So, this Marc comments. prepared in mentioned

residual seeing improvements also in in A patients. you're are consistent We are XX in what pVOX right. And those with Cohort a X seeing of that saw we gradient

gradient significant. there the statistically reduction So, is and

function improvements very is correlated learn get going dose that to to to know we to patients, the obstruction that much information symptoms we're So, and in we forward and our to is to able we that be alleviate here the plan which to able is us do help exactly really to what lock EXPLORER. pleased want we're what want really down and in

So, you're seeing dose any there response, the lower further? dose push even is think based results do higher thought dose on in a starting patients to to need dose you albeit here a perhaps the a in there's

what of dosing think concentration that is getting this XX range might I in X majority milligrams. the patients data the suggesting and into likely vast right is require between

commonly know as ability And the know imaging the prescribers so, you caregivers very technique, be have the gradients. well and echocardiography monitor to able we with that to used a

help get adjust mavacamten. we to we is that think dose to target can with in and so, the to that into I And alleviate in the tool required echocardiography fantastic development with concentration clinical practice which clinical range, have also a guide order obstruction

A? pVOX correlation And this part is B just and question improvement between earlier, gradient if it part you may - was could, similar and in a the final but as have just I LVOT mentioned

your that in a precise indeed, small hard surgical it's the we in know seen in with of data the being definitely Cohort draw saw with still been patients, But with to relatively seeing that to to gradient you all so is very what correlations. the improvement B consistent It is pVXX is number well. ability reduce and injections past A. that seeing in interventions It's that's medication. think our I catheter-based we're Yes, has consistent related seen Cohort as of we're what

taking Great. Thanks for questions. the

next our Security. David Nierengarten question And Wedbush Instruction]. [Operator from you. Thank

now Your open. is line

I the how have you're taking start mean you. for effective confident here, are questions. where that and a on about are trial confident thanks then multiple and a of a thinking bit the be about dosing lead might obviously Phase guess, you to a Hey that question? doses? guess able how for a you in actually right still the range have I thinking are you you we have how confident have schedule the going I couple design with you end maintenance so a Maybe dose X you doses how on doses the dose I to many how and are first or little are arms

David. Hey

in clarify like we've seen - So, we've it's to like important PIONEER. done that

that low single is expectation start we on dose. will Our a

or patients So, order as dose the be PIONEER we we lowest measurements that where believe then we've in study like is mentioned into in with determine the capacity. in reduction that done the able which on And symptom a dose that maintain just gradient Mike take be we is dose achieve increase on. functional we're improvements we'll will to all to to are based and pivotal learning our of echocardiographic whether predictive

Okay. maybe Thanks. how help out to which a that you basically? do That question my maintain on leads us on in blind is next situation how you actually

Development June This Chief Lee Officer, Chief is Officer. and Operating

of readers site doses. will all for that be happened to central because the So, in at sent in pivotal will n changes the for have this be the into line IFRS tests the study maintained Drug incorporation

planning this get read maintaining information are Central So, goes and all level that's to site blind. IFRS or investigator. on not to the how we translated It of the via does Incorporation

not presume to follow-up use of how part is the also that blockers variability a patients the add because I there, question want on plan do to beta maintain the beta blocker who on plan? patients then And you Phase X prevent Billion, you blinding to that stopped quickly in and the their Cohort that

baseline No, of there beta out clear, patients of on to were discontinuation be just is the beta just David, not. on one that one was patient that there no XX blocker X was blocker. one

Oh, it was not.

entire whatever to stay protocol background period from they're through the on and through the make baseline medications -- point, will I treatment precisely think want what is on your that sure require. patients that's So, we

Got Thanks. Okay. it.

today. to turn call closing our Thank you. to And like for the Tassos remarks. that Gianakakos session concludes for over question-and-answer I'd back

Glenda XXXX, of to momentum continued XXXX's our today across which portfolio potential to joining of everybody continued be and your support Thanks promises and has thanks us progress carried therapies. MyoKardia for our of year mission. for and us a into

So, while deep remain attention will our much research company of innovative to our mavacamten's on indeed pivotal bold and commitment study, continues.

create team's science breakthrough address alleviate the function to expect to we further passion improve patients study, ability evidence into many the quarter move for EXPLORER Our as and therapies helping us confidence are in and of increases and fueling biology targeted is that help symptoms cardiovascular in in with which year. pivotal to devastating the obstruction diseases. designed this provides obstructive discoveries the us second HCM underlying causes of do dataset we mavacamten's Today's our

designed are start. before protocol regulatory X EXPLORER a HCM trial the update We finalizing the Phase and study on X to trial Phase share plan

the progress a Phase XB announced patients any to MYK-XXX, underway and read heart little helping and our very to across research platform, trial to of half is form in range half study sharing the to we're we're if trial We'll designed for XXXX you you DCM particularly move enable with currently for of novel into Phase take challenging address topline And data So, year just which which to earlier nonobstructive important Phase teams in of treatment our data a in therapies additional us the later in disorders. muscle the how we're X includes to study this we this of progress of X you recently looking clinical forward from our year, this MAVERICK XXX novel with expand discovery enrolling we of out milestone, quarter targeted heart study, on begin -- failure. that patients. clinical options. HCM, updating clinical a on mavacamten programs, showing and looking anticipated a preclinical clinical plan HCM from our report DCM addition disease programs treatment second gaining of Phase insights to and the when the the also X trial stable for That initiation throughout with year second our we expect the biology to topline enabled of

So, you over in weekend Conference thanks everyone and We hope Cowan to Healthcare at at again week. ACC the in and see the of Boston afternoon and evening. a have the next great many Orlando

for participation gentlemen, today's and thank now great concludes you and your conference. Ladies disconnect. a Everyone in have you This the program may day.